Compare Eli Lilly And Co (LLY) vs Verizon Communications Inc (VZ) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Verizon (VZ) trades at $43.51, down 0.19% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 10.63 and consistent earnings beats, including Q1 2026 EPS of $1.28 versus $1.21 expected. Recent news highlights a restructuring involving 3,000 job cuts and retail store divestitures to franchisees, aimed at improving efficiency. Cash flow from operations remains robust at $37.14 billion for 2025, supporting a dividend yield near 6.7%.

VZ offers value with low valuation multiples and a high dividend, but faces headwinds from intense wireless competition and execution risks in restructuring. Analyst consensus is a 'Hold' with a $48.06 price target, implying 10% upside. Key risks include debt levels and market saturation, while potential catalysts include successful cost-cutting and broadband growth.